Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

30.03 -0.36 (-1.18%)
Streaming Delayed Price Updated: 11:38 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat ↗
The stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug. 
Via Investor's Business Daily
Topics Earnings
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments ↗
Travere Therapeutics (TVTX) Q3 2025 earnings crush expectations, driven by strong FILSPARI sales. Revenue soared 160% year-over-year, sparking an 11.7% stock surge. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Travere Therapeutics Reports Third Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Report Third Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup ↗
Travere Therapeutics (TVTX) shows strong growth momentum with accelerating earnings and revenue. Its high technical rating and clear setup pattern offer a compelling investment case. 
Via Chartmill
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts ↗
 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Shares Are Trading Higher Wednesday: What's Going On? ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High ↗
Shares shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug. 
Via Investor's Business Daily
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application ↗
Via Stocktwits
News headline image
Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism
From Travere Therapeutics, Inc.
Via Business Wire
News headline image
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
News headline image
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch ↗
The company has made a name for itself with a drug that treats a progressive kidney condition. 
Via Investor's Business Daily
News headline image
Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.